...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of ocular pharmacology and therapeutics: The official journal of the Association for Ocular Pharmacology and Therapeutics >Pharmacotherapy compliance in patients with ocular hypertension or primary open-angle glaucoma.
【24h】

Pharmacotherapy compliance in patients with ocular hypertension or primary open-angle glaucoma.

机译：高眼压或原发性开角型青光眼患者的药物治疗依从性。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: The aim of this study was to compare rates of pharmacotherapy coverage in patients with ocular hypertension (OH) and patients with primary open-angle glaucoma (POAG). METHODS: Retrospective cohort study analysis of a nationally representative, multimanaged health plan database (PharMetrics; 1998-2005) which included 4818 medicated OH patients and 52,985 medicated POAG patients with at least 1 year of continuous enrollment and at least one prescription for IOP-lowering medication during the first year of follow-up. Patients selected for the current study were nested within the cohort of OH patients (n = 36,767) and POAG patients (n =72,412) previously reported. Of the previously reported OH cohort, only 13.1% of patients filled at least one prescription, as compared to 73.2% of the previously reported POAG cohort. Medication coverage was defined as the percent of days during which a patient was in possession of IOP-lowering therapy over the first year of follow-up (medication coverage = number of covered days/365). Compliant patients were defined as those with >or= 75th percentile medication coverage. RESULTS: POAG patients had slightly longer mean length of enrollment in the database (2.5 years, SD = 1.2) than did OH patients (2.4 years, SD = 1.1; P < 0.0001). The mean medication coverage was 50% for the POAG cohort (SD = 0.26) and 40% for the OH cohort (SD = 0.25; P < 0.0001). In multivariate models controlling for key covariates of interest, POAG patients were 1.9 (95% CI: 1.7 to 2.0) times more likely to be compliant with their pharmacotherapy than OH patients. CONCLUSION: In general, pharmacotherapy coverage was poor. Patients with POAG, a more severe condition, were significantly more covered with pharmacotherapies than patients with OH. It is important to implement strategies to help improve patient coverage prior to occurrence of more severe disease.
机译：目的：本研究的目的是比较高眼压（OH）患者和原发性开角型青光眼（POAG）患者的药物治疗覆盖率。方法：一项具有全国代表性的多管理健康计划数据库（PharMetrics; 1998-2005年）的回顾性队列研究分析，其中包括4818例药物OH患者和52,985例POAG药物患者，这些患者连续入组至少1年，并且至少有一项降低IOP的处方在随访的第一年服药。选择用于本研究的患者被嵌套在先前报道的OH患者（n = 36,767）和POAG患者（n = 72,412）中。在先前报告的OH队列中，只有13.1％的患者至少填写了一张处方，而先前报告的POAG队列为73.2％。药物覆盖率定义为随访第一年患者接受降低IOP疗法的天数百分比（药物覆盖率=覆盖天数/ 365）。依从性患者定义为药物覆盖率≥75％的患者。结果：POAG患者在数据库中的平均入组时间（2.5年，SD = 1.2）比OH患者（2.4年，SD = 1.1; P <0.0001）更长。 POAG队列的平均药物覆盖率为50％（SD = 0.26），OH队列的平均药物覆盖率为40％（SD = 0.25; P <0.0001）。在控制感兴趣的主要协变量的多元模型中，与OH患者相比，POAG患者接受药物治疗的可能性高1.9倍（95％CI：1.7至2.0）。结论：总体而言，药物治疗覆盖率较差。状况较严重的POAG患者比OH患者的药物治疗覆盖率更高。重要的是在更严重的疾病发生之前，实施有助于改善患者覆盖率的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号